| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CMA1 |
| Uniprot No | P23946 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-247aa |
| 氨基酸序列 | IIGGTECKPHSRPYMAYLEIVTSNGPSKFCGGFLIRRNFVLTAAHCAGRSITVTLGAHNITEEEDTWQKLEVIKQFRHPKYNTSTLHHDIMLLKLKEKASLTLAVGTLPFPSQFNFVPPGRMCRVAGWGRTGVLKPGSDTLQEVKLRLMDPQACSHFRDFDHNLQLCVGNPRKTKSAFKGDSGGPLLCAGVAQGIVSYGRSDAKPPAVFTRISHYRPWINQILQAN |
| 预测分子量 | 29.0kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CMA1(Chymase 1)重组蛋白的模拟参考文献示例(非真实文献，仅供格式参考)：
1. **文献名称**：*Expression and Purification of Recombinant Human CMA1 in Insect Cells*
**作者**：Smith A, et al.
**摘要**：研究利用杆状病毒-昆虫细胞系统高效表达重组人CMA1.并通过亲和层析纯化，验证其酶活性及稳定性，为炎症性疾病研究提供工具蛋白。
2. **文献名称**：*Functional Characterization of Recombinant CMA1 in Fibrosis Models*
**作者**：Lee J, et al.
**摘要**：通过哺乳动物细胞表达重组CMA1.证明其在体外促进成纤维细胞胶原合成，提示CMA1在组织纤维化中的潜在作用机制。
3. **文献名称**：*Crystal Structure Analysis of Recombinant CMA1-Protease Complex*
**作者**：Zhang Y, et al.
**摘要**：解析重组CMA1与抑制剂的复合物晶体结构，揭示其底物结合位点特征，为设计靶向CMA1的抑制剂提供结构基础。
(注：以上文献为模拟内容，实际研究中建议通过PubMed、Google Scholar等平台检索真实文献。)
**Background of CMA1 Recombinant Protein**
Chymase 1 (CMA1), a serine protease primarily stored in mast cell granules, plays critical roles in tissue homeostasis and inflammatory responses. It is synthesized as an inactive pro-enzyme and activated upon release into the extracellular matrix, where it cleaves substrates such as angiotensin I, transforming it into angiotensin II—a key regulator of blood pressure and fibrosis. CMA1 also processes extracellular matrix proteins, cytokines, and growth factors, influencing processes like wound healing, tissue remodeling, and immune regulation.
Dysregulated CMA1 activity is implicated in pathologies including cardiovascular diseases (e.g., hypertension, aneurysms), fibrotic disorders (e.g., cardiac fibrosis), and allergic inflammation. Its role in angiotensin II generation independent of the ACE pathway highlights its potential as a therapeutic target. Recombinant CMA1 protein, produced via heterologous expression systems (e.g., mammalian or insect cells), retains enzymatic activity and structural integrity, enabling functional studies.
Researchers utilize recombinant CMA1 to investigate protease mechanisms, screen inhibitors, and model disease pathways. Its application aids in developing targeted therapies to modulate CMA1-driven pathologies while minimizing off-target effects. Additionally, recombinant CMA1 serves as a tool to study mast cell biology and protease interactions in complex biological systems. Understanding CMA1's dual role in health and disease underscores its significance in both basic research and translational medicine.
×
